HOUSE_OVERSIGHT_025888.jpg
1.32 MB
Extraction Summary
4
People
4
Organizations
1
Locations
0
Events
1
Relationships
1
Quotes
Document Information
Type:
Email
File Size:
1.32 MB
Summary
This document is an email from Sultan Bin Sulayem to Jeffrey Epstein dated July 24, 2015. Sulayem forwards a Forbes article regarding the FDA approval of a new cholesterol-lowering drug called Praluent (by Regeneron Pharmaceuticals) and asks Epstein if he has heard of it. The document bears a House Oversight Bates stamp.
People (4)
| Name | Role | Context |
|---|---|---|
| Sultan Bin Sulayem | Sender |
Sent an email to Jeffrey Epstein inquiring about a cholesterol drug.
|
| Jeffrey Epstein | Recipient |
Received email at jeevacation@gmail.com.
|
| Matthew Herper | Journalist |
Author of the Forbes article forwarded in the email.
|
| Steven | Source |
Person quoted in the article (last name cut off).
|
Organizations (4)
| Name | Type | Context |
|---|---|---|
| Forbes |
Publisher of the article.
|
|
| FDA (Food and Drug Administration) |
Government body mentioned in the article headline.
|
|
| Regeneron Pharmaceuticals |
Biotech company mentioned in the article as the inventor of the drug.
|
|
| House Oversight Committee |
Source of the document (indicated by footer).
|
Locations (1)
| Location | Context |
|---|---|
|
Location of Regeneron Pharmaceuticals.
|
Relationships (1)
Direct email exchange sharing health/medical news.
Key Quotes (1)
"Have you heard of this colestrol"Source
HOUSE_OVERSIGHT_025888.jpg
Quote #1
Full Extracted Text
Complete text extracted from the document (1,675 characters)
From: Sultan Bin Sulayem [REDACTED]
Sent: 7/24/2015 8:37:24 PM
To: Jeffrey Epstein [jeevacation@gmail.com]
Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today
Sent: 7/24/2015 8:37:24 PM
To: Jeffrey Epstein [jeevacation@gmail.com]
Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today
Importance: High
Have you heard of this colestrol
Jul 24, 2015 @ 3:23 PM 1,169 views
The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot
[Image Placeholder]
Matthew Herper ,
Forbes Staff
I cover science and medicine, and believe this is biology's century.
• Follow on Forbes
(1970)
Forbes Staff
I cover science and medicine, and believe this is biology's century.
• Follow on Forbes
(1970)
•
•
•
•
• Full Bio
• Recent Posts
• Popular Posts
•
•
•
• Full Bio
• Recent Posts
• Popular Posts
I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today. Email me, follow me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page.
Loading...
Loading...
The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins.
It might be a big step in the battle against heart disease – and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost down the line.
“Obviously, the class is one of the biggest developments in cardiology in the last decade, that will allow us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol,” says Steven
Loading...
The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins.
It might be a big step in the battle against heart disease – and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost down the line.
“Obviously, the class is one of the biggest developments in cardiology in the last decade, that will allow us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol,” says Steven
HOUSE_OVERSIGHT_025888
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document